China’s 2026 Dual-List Draft Workplan: Earlier Innovation Access, Tighter Lifecycle Pricing Discipline
China’s 2026 NRDL draft workplan signals a more integrated, lifecycle-oriented reimbursement framework: earlier access for innovative therapies, closer regulatory–reimbursement alignment anchored in RWE, and tighter pricing discipline for mature and me-too products.
China’s Healthcare System Is Reorganizing: What It Means for Manufacturers
As China’s healthcare system reorganizes, evolving care pathways and payment dynamics are reshaping how access is secured and how value is realized.
RWE and the Quiet Rewiring of China’s Reimbursement System
Five recent policy releases show how real-world evidence is quietly reshaping pricing, reimbursement, and clinical adoption for both innovative and established medicines in China.
Three Shifts Reshaping China’s Drug Payment System: Implications for Global Pharma
China’s drug payment system is shifting from isolated policy levers toward an environment defined by their interaction. Recent signals are beginning to link pricing, launch timing, and multi-payer access in ways that materially change how global pharma approaches China.
From Reference Tool to Operating Model: A Roadmap for China’s C-List
China’s C-List establishes a national reference for innovative drugs outside the NRDL—but not yet a payment system. Its impact will hinge on whether insurers and regulators can turn policy intent into a workable, risk-sustainable commercial coverage model.
China Establishes Market-Price Database, Reshaping Global Pricing Signals
China’s new drug price database marks a subtle but important shift in price governance—separating how market prices are recorded from how reimbursement is negotiated. The change reshapes pricing signals in ways that matter for both domestic innovators and multinational firms.
China’s Biosimilar VBP: Emerging Rules, Pricing Dynamics, and What Early Signals Suggest
China’s VBP is shifting toward biosimilars, raising strategic questions for global manufacturers: Will the country cultivate an EU-style biosimilar market—and will VBP mirror generics or follow a modified path? This series interprets early policy signals to help companies prepare.
NFRA’s Guiding Opinions: What They Mean for China’s Multi-Level Coverage Framework
NFRA’s latest Guiding Opinions signal a shift toward a more innovation-friendly commercial health insurance ecosystem. The article unpacks five key policy themes with critical implications for the C-List rollout and the building of China’s multi-level coverage framework.
Winning in China in a Multi-Level Coverage Era for Global Pharma
Success in China’s multi-level coverage era will hinge on three imperatives that upend old models and open new pathways.
▶️Making the C-List Work: Lessons and Next Steps for Pharma
The final Health Policy and Financing Panel wrapped up the C-List Masterclass with reflections, insurer perspectives, global case studies, and Q&A—highlighting how manufacturers can turn C-List inclusion into a true springboard for coverage.
